Paul Hudson, head of one of the world’s largest pharmaceutical companies, says leaders need to sit back and listen more often.

Sanofi/GSK launch Phase III trial of COVID-19 vaccine, will test efficacy against variants

Rodillas sin dolor

The company said the vaccine gives a 95.5% protection against severe dengue and an 80.3% reduction in the risk of hospitalisation.

The partners expect to begin clinical studies of the compound later this year

Coronavirus COVID 19 vaccine news, latest update, human trials: Sanofi's Pasteur division has an established track record in influenza vaccines. Last month it had teamed with its British rival GSK to produce a vaccine candidate hoping that it will be ready in 2021.

(United States Federal Circuit) - Affirming the district court's rulings in the case of a patent infringement claim relating to cardiovascular drugs where the court held that the plaintiff had proven that the defense's sale of proposed generic drugs with their proposed labels would induce physicians to infringe, and holding that none of the patents were invalid for obviousness.

BCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data, the firms note

First, let me say thank you to all of the healthcare workers who are putting themselves at risk during this crisis.

As I noted last week, many of the crucial issues for our healthcare system will remain after we all get through this challenging period. In that regard, here’s a look at some noteworthy news from the past month:

• Sanofi discloses new data about insulin prices

• Excellent new academic research on list vs. net drug prices

• Three notable researchers overturn their earlier research on drug costs

• Amazon switches PBM vendors for some of its employees

Plus, we unveil the teaser trailer for Drug Channels Video!

P.S. Join the more than 9,000 followers of my daily links to neat stuff at @DrugChannels on Twitter. My recent tweets have highlighted such topics as:

• How GoodRx shares patients’ prescription data
• 2019 drug trend at Prime Therapeutics
• Controversy about the independent pharmacy market
• A new $5 generic mail order program, Medicare Part D reform
• Retail pharmacy’s future
• Job openings at Amazon 
• Frozen cookie dough
• And much more!

I have also been tweeting many under-the-radar stories about how the coronavirus affects drug channels.
Read more »

Two companies jointly have capacity to manufacture hundreds of millions of doses

• Coronavirus – latest updates
• See all our coronavirus coverage

Two of the world’s biggest vaccine companies have joined forces in an “unprecedented” collaboration to develop a Covid-19 vaccine.

GlaxoSmithKline and Sanofi, which combined have the largest vaccine manufacturing capability in the world, are working together on a hi-tech vaccine they say could be in human trials within months.

What is Covid-19?

Continue reading...

Sanofi’s MedQuadfi Meningococcal Conjugate Vaccine has scored FDA approval for the prevention of invasive meningococcal disease, becoming the first and only product available in the US for this indication in patients of at least two years old.

Sanofi and Regeneron’s have lifted the lid on new topline data on their PD-1 inhibitor Libtayo (cemiplimab) in patients with advanced basal cell carcinoma (BCC), the most common skin cancer in the world, with around two million new cases diagnosed each year in the US alone.

Drug has shown “clinically meaningful responses” for basal cell carcinoma

Sanofi-Aventis U.S. Inc. and Sanofi-Aventis U.S. LLC, subsidiaries of international drug manufacturer Sanofi (collectively, Sanofi US), have agreed to pay $109 million to resolve allegations that Sanofi US violated the False Claims Act by giving physicians free units of Hyalgan, a knee injection, in violation of the Anti-Kickback Statute, to induce them to purchase and prescribe the product. The settlement also resolves allegations that Sanofi US submitted false average sales price (ASP) reports for Hyalgan that failed to account for free units distributed contingent on Hyalgan purchases. The government alleges that the false ASP reports, which were used to set reimbursement rates, caused government programs to pay inflated amounts for Hyalgan and a competing product.

Editor's note: This story was originally published Friday morning, and has been updated to reflect the FDA's decision regarding the drug later that day. A U.S. approval decision for a major drug planned to be marketed by Cambridge-based Sanofi Genzyme that had been expected last Friday has been delayed due to “deficiencies” found during a manufacturing site inspection in France. In its third quarter report, released Friday morning, French drugmaker Sanofi (NYSE: SNY) disclosed that “manufacturing…

• Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group

The company receives approval for MenQuadfi to prevent meningococcal disease.

Sanofiâs insulin aspart biosimilar receives positive opinion from the EMAâs CHMP.

Sanofi and Regeneron’s Dupixent has become a popular treatment for atopic dermatitis and asthma. Now, a research team in Japan has discovered that IL-4 and its receptor—which Dupixent inhibits—could be promising targets for treating the eye disease age-related macular degeneration.

Rodillas sin dolor

French pharmaceutical company Sanofi is ready to offer the French authorities, millions of doses of Plaquenil containing hydroxychloroquine, to treat

Pharma company’s use of algorithms marks fast-growing trend in big digitally-savvy markets including India

BCCLSanofi plans to get thousands of subjects onboard across the world for the trials of experimental coronavirus vaccines that it is developing with GSK. Once enrolled, the company will start early-stage trials in September. The pharma giant has already partnered with GlaxoSmithKline Plc (GSK) and is researching also exploring other options simultaneously. It hopes to introduce the vaccine next year, reported Reuters.Sanofi, a French multinational pharmaceutical company, says it is working on two different projects to develop a vaccine for COVID-19. The pharma giant has partnered with GlaxoSmithKline Plc (GSK) and is researching other options as well. It hopes to introduce the vaccine by next year, reported Reuters. The plan is to get thousands of subjects on board across the world to test

French drugmaker Sanofi SA said it plans to enroll thousands of subjects globally for trials of an experimental vaccine for the coronavirus it is developing with GlaxoSmithKline Plc, and that it has started to discuss advanced purchases with several countries. Sanofi teamed with British rival GSK to come up with a candidate it hopes will be ready next year.

Venture will combine six active pharmaceutical ingredient production sites in Europe

Venture will combine 6 active pharmaceutical ingredient production sites in Europe

New study explores whether dampening IL-6 could address serious coronavirus infections

The partners expect to begin clinical studies of the compound later this year